TCH-017 Eye Drops Made from Platelet-Rich Plasma: Development and Use of a New Master Formula

Abstract

TechnologyEur J Hosp Pharm 2013;20(Suppl 1):A1-238 A75anhydrous, 50 mL of sterile water and simple syrup. The phosphorus strength of 67.4 mg/mL is close to that of Phosphoneuro. For 12 weeks, the solution appeared unchanged, clear and colourless. pH about 4.14 remained constant. Sodium and phosphorus contents were stable and the observed values were within 10% of the theoretical values. Microbiological results were in accordance with European Pharmacopeia: viable aerobic bacteria ≤ 10 3 (CFU/ml), fungal ≤ 10 2 , no E.coli. Conclusions Microbiological compliance and physicochemical stability were verified at 12 weeks according to the standards of the European Pharmacopeia. After users had insisted, the French Regulatory agency urged Bouchara Recordati to produce Phosphoneuros again, effective in May 2012. This is an example of the hospital pharmacist's role in compounding drugs to allow patients to continue their treatment in case of shortages of commercial products.No conflict of interest. Background Information and communication technologies increase efficiency and safety in health systems. The SiMON protocol (Monitored Information System), developed by the R&D department of hospital's Computing Service, provides a tool for monitoring patients attending a particular consultation and is adaptable in line with the needs of each clinical service. Its main objective is to streamline care by automating patient information related to such consultation. Furthermore, it provides a record for future analysis of information collected, making it possible to export information, scorecards and predict comorbidities. Purpose To describe the implementation of SiMON in pharmaceutical monitoring of patients with viral diseases (HIV/HCV). ImplementatIon of a monItored InformatIon Materials and MethodsReview of antiretroviral technical datasheets, pegylated interferon, ribavirin and protease inhibitors (boceprevir/telaprevir) and of the necessary literature to collect criteria and general recommendations for treatment of these diseases, adverse drug effects, interactions between these drugs and others, and contraindications for use. Results In order to implement SiMON in the pharmaceutical monitoring of patients with HIV/HCV, the Pharmacy Service reviewed 15 datasheets of antiviral drugs. Usage alerts were established as well as recommendations for each drug that depend on patient data (83 alerts), prescribed dosage (34 alerts), laboratory test results (94 alerts) and interactions between different medicinal products (484 alerts). Each of these alerts can refer to a contraindication or usage precaution, with a possible recommendation to suspend treatment, adjust the dose or change the drug involved in the interaction for an alternative. We also collected 482 adverse drug effects that had to be structured in tree form so they could be encoded by the Computing Service. Conclusions The SiMON protocol, a tool that increases the efficiency of patient monitoring in a multidisciplinary way, makes it possible to record side effects and g...